Emalex Bioscience is developing a new treatment for Tourette Syndrome. The disease affects around 1 in 160 children and has no cure. Emalex founder Jeff Aronin says clinical trial results for a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback